Biohaven Pharmaceutical Holding Company Ltd represents a set of values and corporate philosophy that revolve around developing innovative therapies to improve the lives of patients with neurological and neuropsychiatric diseases. The company is committed to scientific excellence, integrity, and collaboration to drive advancements in the field of neuroscience. Biohaven prioritizes patient-centricity, ensuring access to its therapies and delivering value to stakeholders. With a focus on research and development, Biohaven aims to inspire hope and create a positive impact on the healthcare industry. As a leading pharmaceutical company, Biohaven Pharmaceutical Holding Company Ltd strives to enhance patient outcomes through its commitment to science, integrity, and collaboration.

Biohaven Pharmaceutical Holding Company Ltd is primarily present in the United States.

Biohaven Pharmaceutical Holding Company Ltd has achieved several significant milestones. The company successfully received U.S. FDA approval for their migraine treatment, rimegepant, which brings new hope for patients suffering from migraines. In addition, Biohaven obtained FDA breakthrough therapy designation for their experimental treatment, troriluzole, in spinocerebellar ataxia, a neurodegenerative disorder. The company also secured a global licensing agreement with Bristol Myers Squibb for the development and commercialization of their oral small molecule glutamate modulating agents. These accomplishments highlight Biohaven Pharmaceutical Holding Company Ltd's dedication to advancing innovative therapies to address unmet medical needs.

Biohaven Pharmaceutical Holding Company Ltd is a renowned biopharmaceutical firm that focuses on developing innovative therapies for neurological diseases. Established in 2013, Biohaven has rapidly emerged as a key player in the industry. Their dedicated team of scientists and researchers work diligently to discover and develop new treatments to improve the lives of patients suffering from conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, and migraine. With a commitment to innovation and a strong pipeline of potential therapies, Biohaven Pharmaceutical Holding Company Ltd continues to make significant contributions to the field of neuroscience.

The main competitors of Biohaven Pharmaceutical Holding Company Ltd in the market include pharmaceutical companies such as AbbVie Inc., Eli Lilly and Company, and Johnson & Johnson. These companies are also active in the field of developing and commercializing pharmaceutical products, including therapies for neurological and neurodegenerative disorders. During its market presence, Biohaven Pharmaceutical Holding Company Ltd has demonstrated its ability to compete with these industry giants by innovating and developing unique treatment options. As Biohaven continues to advance its research and development, it strives to maintain a competitive edge within the pharmaceutical market.

Biohaven Pharmaceutical Holding Company Ltd is primarily active in the pharmaceutical industry.

The business model of Biohaven Pharmaceutical Holding Company Ltd is focused on the development and commercialization of innovative therapies to address unmet medical needs. As a pharmaceutical company, Biohaven aims to deliver novel treatments in neurological and neuropsychiatric diseases. Their business model involves conducting research, clinical trials, and seeking regulatory approval for their potential drug candidates. Through strategic partnerships and collaborations, Biohaven aims to bring their promising therapies to the market, benefiting patients worldwide. By combining scientific expertise with a strong commitment to patient care, Biohaven Pharmaceutical Holding Company Ltd strives to make a significant impact in the field of neurology and neurosciences.

Biohaven Pharmaceutical Holding Company의 P/E 비율은 -2.95입니다.

Biohaven Pharmaceutical Holding Company의 P/S 비율은 61.75입니다.

Biohaven Pharmaceutical Holding Company에 대한 AlleAktien 품질 점수는 2/10입니다.

예상되는 Biohaven Pharmaceutical Holding Company 매출은 41.19 백만 USD입니다.

예상되는 Biohaven Pharmaceutical Holding Company 이익은 -863.19 백만 USD입니다.

The Biohaven Pharmaceutical Holding Company Ltd is a biopharmaceutical company focused on the development and commercialization of innovative therapies for neurological disorders. It was founded in 2013 and is headquartered in New Haven, Connecticut. Biohaven conducts research and development programs for a variety of diseases, including migraine, Alzheimer's, stroke, schizophrenia, and anxiety disorders. The company's main activities include the discovery and development of drugs based on its proprietary molecules, including small molecules and antibodies. It focuses on developing novel therapies targeting the needs of patients suffering from severe or rare neurological disorders. Biohaven's Piperazine Analog Scale (PAS) and especially the CGRP inhibitor Rimegepant have been successfully tested in Phase III clinical trials for the treatment of migraine. The initial results show a significant improvement in migraine frequency, with average results decreasing from over 4.8 migraine days per month to less than 0.8 days per month for patients, with a risk of side effects of less than 2%. Biohaven's focus is on developing therapies for neurological disorders that have been inadequately treated or have no effective therapy available. In close collaboration with leading neuroscientists and researchers, research and development programs are underway to create novel therapies for Alzheimer's, stroke, and schizophrenia. Biohaven places great emphasis on comprehensive and thorough clinical evaluation. Clinical studies are conducted in close collaboration with experienced clinical researchers and experts to adhere to the highest standards of clinical development. The company also focuses on creating strategic partnerships to further expand and scale its development programs globally. For example, in June 2020, Biohaven signed a partnership with the Chinese pharmaceutical company Royalty Pharma to ensure the distribution and marketing of Rimegepant in the Chinese market. Ultimately, Biohaven aims to provide better care for patients, caregivers, and healthcare providers in neurological disorders with innovative therapies. The company aims to become a leading player in neurology, continuing to grow through its successes in medical research and development.

Biohaven Pharmaceutical Holding Company은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Biohaven Pharmaceutical Holding Company의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Biohaven Pharmaceutical Holding Company의 ISIN은 VGG111961055입니다.

Biohaven Pharmaceutical Holding Company의 WKN은 A2DQ7W입니다.

Biohaven Pharmaceutical Holding Company의 티커는 BHVN입니다.

지난 12개월 동안 Biohaven Pharmaceutical Holding Company은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Biohaven Pharmaceutical Holding Company은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Biohaven Pharmaceutical Holding Company의 현재 배당 수익률은 입니다.

Biohaven Pharmaceutical Holding Company은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Biohaven Pharmaceutical Holding Company은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Biohaven Pharmaceutical Holding Company은 '건강' 섹터에 속합니다.

Biohaven Pharmaceutical Holding Company의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Biohaven Pharmaceutical Holding Company는 0 USD를 배당금으로 지급했습니다.

Biohaven Pharmaceutical Holding Company의 배당금은 USD에 지급됩니다.